During the past decade, SMIQ, S. de R.L. de C.V. conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SMIQ, S. de R.L. de C.V." #1 sponsor was "Pfizer" with 3 trials, followed by "Mallinckrodt" with 2 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "CanariaBio Inc." with 1 trials sponsored and "Enanta Pharmaceuticals, Inc" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SMIQ, S. de R.L. de C.V." #1 collaborator was "Advaccine (Suzhou) Biopharmaceuticals Co., Ltd." with 1 trials as a collaborator, "Gynecologic Oncology Group" with 1 trials as a collaborator, "Iqvia Pty Ltd" with 1 trials as a collaborator, "Regeneron Pharmaceuticals" with 1 trials as a collaborator and "West China Hospital" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "SMIQ, S. de R.L. de C.V." are "Dermatitis, Atopic" (2 trials), "Arthritis, Rheumatoid" (1 trials), "COVID-19" (1 trials), "COVID-19 Disease" (1 trials) and "Carcinoma, Ovarian Epithelial" (1 trials). Many other conditions were trialed in "SMIQ, S. de R.L. de C.V." in a lesser frequency.

Most popular intervention types in "SMIQ, S. de R.L. de C.V." are "Drug" (11 trials), "Other" (4 trials), "Biological" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Acthar Gel" (2 trials), "0 mg Induction ONLY" (1 trials), "150 mg Induction/Chronic" (1 trials) and "450 mg Induction/Chronic" (1 trials). Other intervention names were less common.

The vast majority of trials in "SMIQ, S. de R.L. de C.V." are 11 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "SMIQ, S. de R.L. de C.V.". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in SMIQ, S. de R.L. de C.V., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in SMIQ, S. de R.L. de C.V., 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".